Combretastatin and Checkpoint Antibody Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using Vascular Disrupting Agents (VDAs) often result in rapid tumor regrowth due to revascularization, as they primarily cause acute shutdown of tumor vasculature without effectively inhibiting tumor-associated angiogenesis and immune system responses.
Innovation Solution
Combining a combretastatin agent with CTLA-4, PD-1, and PD-L2 antibodies to disrupt tumor vasculature and enhance immune responses, thereby inhibiting tumor regrowth and angiogenesis synergistically.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If Vascular Disrupting Agents (VDAs) are used to disrupt tumor vasculature, then acute shutdown of tumor blood flow is achieved, but rapid tumor regrowth occurs due to revascularization
Solution Approach 1:
The patent combines VDAs with immunomodulating agents (checkpoint inhibitors targeting CTLA-4, PD-1, PD-L1, or PD-L2) to create a dual-mechanism therapy. The VDA provides immediate vascular shutdown while the immunomodulating agent sustains anti-tumor immunity to prevent regrowth, resolving the contradiction between fast action and long-lasting effect
Solution Approach 2:
The immunomodulating agent provides continuous immune system activation against tumor cells after VDA-induced vascular shutdown. This continuous immune pressure prevents the tumor from regenerating new blood vessels and regrowing, extending the duration of anti-tumor effect beyond the initial vascular disruption
2Reliability
If VDA monotherapy is administered, then tumor vasculature is disrupted, but tumor-associated angiogenesis and immune responses are not effectively inhibited
Solution Approach 1:
The patent merges VDA therapy with immunomodulating therapy to address multiple tumor defense mechanisms simultaneously. While VDA reliably disrupts vasculature, the added immunomodulating component targets immune checkpoint pathways, providing comprehensive coverage against both vascular and immune-mediated tumor survival mechanisms
3Productivity
If combination therapy with VDA and immunomodulating antibodies is used, then synergistic anti-tumor effects are achieved, but treatment complexity increases
Solution Approach 1:
The patent combines two distinct therapeutic mechanisms (VDA and immunomodulating antibodies) into a unified treatment regimen. This merging achieves synergistic anti-tumor effects by simultaneously targeting vasculature and immune pathways, with the combination proven to be more effective than either agent alone despite increased regimen complexity
Data Source
AI summary
Methods for producing an anti-tumor effect in a subject suffering from a cancer or a tumor are disclosed. The methods comprise administering to the patient a Vascular Disrupting Agent (VDA) that a combretastatin agent and one or more antibodies selected from the group consisting of: a CTLA-4 antibody, a PD-1 antibody, a PD-L1 antibody, and a PD-L2 antibody in amounts effective therefor. Examples of combretastatin include CA1P, CA4P, and their corresponding salts and prodrugs. The combination of the VDA and one or more of the antibodies produced a synergistic anti-tumor effect.